Methyltrosine, commonly known as metyrosine, is a synthetic amino-acid derivative and tyrosine hydroxylase inhibitor used in pharmaceutical applications involving catecholamine production. It reduces the synthesis of catecholamines such as dopamine, norepinephrine and epinephrine by inhibiting the enzyme tyrosine hydroxylase.
Methyltrosine is primarily associated with the management of pheochromocytoma, particularly when reduction of excessive catecholamine production is required. It is an important pharmaceutical ingredient for specialized endocrine and cardiovascular applications.
Methyltrosine API is used for qualified pharmaceutical manufacturing, formulation development, analytical testing and research applications.
Methyltrosine inhibits tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis. By reducing the conversion of tyrosine to L-DOPA, it decreases the subsequent production of dopamine, norepinephrine and epinephrine.
This reduction in catecholamine synthesis makes methyltrosine useful in pharmaceutical management of conditions involving excessive catecholamine production.
Methyltrosine API is associated with:
The approved indications and dosage forms depend on the specific pharmaceutical product and applicable regulatory jurisdiction.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| pH (1% Solution) | 5.0–8.0 |
| Individual Impurity | NMT 2.0% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |